These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34191189)

  • 21. Utility of Cardiac Magnetic Resonance Imaging Versus Cardiac Positron Emission Tomography for Risk Stratification for Ventricular Arrhythmias in Patients With Cardiac Sarcoidosis.
    Gowani Z; Habibi M; Okada DR; Smith J; Derakhshan A; Zimmerman SL; Misra S; Gilotra NA; Berger RD; Calkins H; Tandri H; Chrispin J
    Am J Cardiol; 2020 Nov; 134():123-129. PubMed ID: 32950203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis.
    Sgard B; Brillet PY; Bouvry D; Djelbani S; Nunes H; Meune C; Valeyre D; Soussan M
    Clin Radiol; 2019 Jan; 74(1):81.e9-81.e18. PubMed ID: 30482560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late gadolinium enhancement in cardiac sarcoidosis: characteristic magnetic resonance findings and relationship with left ventricular function.
    Watanabe E; Kimura F; Nakajima T; Hiroe M; Kasai Y; Nagata M; Kawana M; Hagiwara N
    J Thorac Imaging; 2013 Jan; 28(1):60-6. PubMed ID: 23249970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis.
    Ohira H; Birnie DH; Pena E; Bernick J; Mc Ardle B; Leung E; Wells GA; Yoshinaga K; Tsujino I; Sato T; Manabe O; Oyama-Manabe N; Nishimura M; Tamaki N; Dick A; Dennie C; Klein R; Renaud J; deKemp RA; Ruddy TD; Chow BJW; Davies R; Hessian R; Liu P; Beanlands RSB; Nery PB
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):259-269. PubMed ID: 26359191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of
    Kaushik P; Patel C; Gulati GS; Seth S; Parakh N; Randeep Guleria ; Kumar R; Gupta P; Bal C
    Ann Nucl Med; 2021 Sep; 35(9):1058-1065. PubMed ID: 34125376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circumferential strain acquired by CMR early after acute myocardial infarction adds incremental predictive value to late gadolinium enhancement imaging to predict late myocardial remodeling and subsequent risk of sudden cardiac death.
    Holmes AA; Romero J; Levsky JM; Haramati LB; Phuong N; Rezai-Gharai L; Cohen S; Restrepo L; Ruiz-Guerrero L; Fisher JD; Taub CC; Di Biase L; Garcia MJ
    J Interv Card Electrophysiol; 2017 Dec; 50(3):211-218. PubMed ID: 29143170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late Gadolinium Enhancement Cardiac Magnetic Resonance Tissue Characterization for Cancer-Associated Cardiac Masses: Metabolic and Prognostic Manifestations in Relation to Whole-Body Positron Emission Tomography.
    Chan AT; Fox J; Perez Johnston R; Kim J; Brouwer LR; Grizzard J; Kim RJ; Matasar M; Shia J; Moskowitz CS; Steingart R; Weinsaft JW
    J Am Heart Assoc; 2019 May; 8(10):e011709. PubMed ID: 31072171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of Assessing Inflammation in Asymptomatic Abdominal Aortic Aneurysms With Integrated 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging.
    Kuzniar M; Tegler G; Wanhainen A; Ahlström H; Mani K; Hansen T
    Eur J Vasc Endovasc Surg; 2020 Mar; 59(3):464-471. PubMed ID: 31708339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Right ventricular involvement is an important prognostic factor and risk stratification tool in suspected cardiac sarcoidosis: analysis by cardiac magnetic resonance imaging.
    Kagioka Y; Yasuda M; Okune M; Kakehi K; Kawamura T; Kobuke K; Miyazaki S; Iwanaga Y
    Clin Res Cardiol; 2020 Aug; 109(8):988-998. PubMed ID: 31872264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic role of serial quantitative evaluation of
    Muser D; Santangeli P; Castro SA; Liang JJ; Enriquez A; Werner TJ; Nucifora G; Magnani S; Hayashi T; Zado ES; Garcia FC; Callans DJ; Dixit S; Desjardins B; Marchlinski FE; Alavi A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1394-1404. PubMed ID: 29610956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocardial Fibrosis in Hypertrophic Cardiomyopathy Demonstrated by Integrated Cardiac F-18 FDG PET/MR.
    Kong EJ; Lee SH; Cho IH
    Nucl Med Mol Imaging; 2013 Sep; 47(3):196-200. PubMed ID: 24900107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary Artery
    Maier A; Liao SL; Lescure T; Robson PM; Hirata N; Sartori S; Narula N; Vergani V; Soultanidis G; Morgenthau A; Kovacic JC; Padilla M; Narula J; Jacobi A; Fayad ZA; Trivieri MG
    JACC Cardiovasc Imaging; 2022 Jan; 15(1):108-120. PubMed ID: 34274283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse Cardiac Events in Cardiac Sarcoidosis Prediction by
    Yamamoto A; Nagao M; Fukushima K; Ando K; Nakao R; Goto M; Matsuo Y; Sakai A; Momose M; Kaneko K; Sakai S; Yamaguchi J
    Am J Cardiol; 2022 Oct; 180():149-154. PubMed ID: 35918233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of cardiac PET/CT with and without phase analysis for detection of scar in cardiac sarcoidosis: Comparison to cardiac magnetic resonance imaging.
    Elwazir MY; Bird JG; AbouEzzeddine OF; Chareonthaitawee P; Blauwet LA; Collins JD; Gibbons RJ; Rodriguez-Porcel M; Kamal HM; Abdellah AT; Bois JP
    J Nucl Cardiol; 2022 Jun; 29(3):1389-1401. PubMed ID: 33474694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility of FDG-PET in myocarditis: Comparison to CMR using integrated PET/MRI.
    Nensa F; Kloth J; Tezgah E; Poeppel TD; Heusch P; Goebel J; Nassenstein K; Schlosser T
    J Nucl Cardiol; 2018 Jun; 25(3):785-794. PubMed ID: 27638745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI.
    Lapa C; Reiter T; Kircher M; Schirbel A; Werner RA; Pelzer T; Pizarro C; Skowasch D; Thomas L; Schlesinger-Irsch U; Thomas D; Bundschuh RA; Bauer WR; Gärtner FC
    Oncotarget; 2016 Nov; 7(47):77807-77814. PubMed ID: 27780922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of serial
    Okafor J; Khattar R; Kouranos V; Ohri S; Diana D; Ebeke E; Azzu A; Ahmed R; Wells A; Baksi AJ; Sharma R; Wechalekar K
    J Nucl Cardiol; 2024 May; 35():101842. PubMed ID: 38479574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability.
    Baer FM; Voth E; Schneider CA; Theissen P; Schicha H; Sechtem U
    Circulation; 1995 Feb; 91(4):1006-15. PubMed ID: 7850935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is positron emission tomography enough to rule out cardiac sarcoidosis? A case report.
    Huang S; Kunchakarra S; Rathod A
    Eur Heart J Case Rep; 2021 Sep; 5(9):ytab300. PubMed ID: 34557632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative assessment of myocardial fibrosis in an age-related rat model by ex vivo late gadolinium enhancement magnetic resonance imaging with histopathological correlation.
    Beliveau P; Cheriet F; Anderson SA; Taylor JL; Arai AE; Hsu LY
    Comput Biol Med; 2015 Oct; 65():103-13. PubMed ID: 26313531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.